Paul Garvin, MD
Transplant Surgery · Saint Louis, MONPI 1407950017
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $216 of the $274 with a category attached, or 79.0%. 8 manufacturers reported payments, led by Amgen at 24.7% of the total. 2024 is the largest year on record at $141, 2.5 times the $57 reported in 2019.
Across 12 payments — averaging $22.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$68
- Z-medica, LLC$57
- Dexcom, Inc.$43
- IBSA Pharma Inc.$30
- Aimmune Therapeutics, Inc.$21
- Embecta Corp.$21
- plus $34 from 2 others
What the payments were for
- Consulting fees$5721%
- Food & beverage$21679%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 3 | $68 |
| Z-medica, LLC | 1 | $57 |
| Dexcom, Inc. | 2 | $43 |
| IBSA Pharma Inc. | 2 | $30 |
| Aimmune Therapeutics, Inc. | 1 | $21 |
| Embecta Corp. | 1 | $21 |
| Nevro Corp. | 1 | $17 |
| Lemaitre Vascular, Inc. | 1 | $17 |
How this compares
Too few transplant surgery providers in Missourito place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Temazepam | 13 | $148 |
| Alprazolam | 18 | $103 |
| Lisinopril | 11 | $39 |
| Lorazepam | 14 | $22 |
Paid to pharmacies, not to this prescriber.
Other transplant surgery in Saint Louis
- Jason WellenSaint Louis$617K
- William ChapmanSaint Louis$8K
- Harvey SolomonSaint Louis$6K
- Jesse DavidsonSaint Louis$4K
- Surendra ShenoySaint Louis$2K
- Mustafa NazzalSaint Louis$245
- Matthew WilkinsonKansas City$9K
- Henry RandallKansas City$2K
- Clark BonhamKansas City$212
- Alice CraneKansas City$186
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.